ZVSA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZVSA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-17), ZyVersa Therapeutics's share price is $4.4872. ZyVersa Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was $27.33. Hence, ZyVersa Therapeutics's PB Ratio of today is 0.16.
The historical rank and industry rank for ZyVersa Therapeutics's PB Ratio or its related term are showing as below:
During the past 4 years, ZyVersa Therapeutics's highest PB Ratio was 6.49. The lowest was 0.00. And the median was 0.00.
During the past 12 months, ZyVersa Therapeutics's average Book Value Per Share Growth Rate was -99.30% per year.
The historical data trend for ZyVersa Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZyVersa Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
PB Ratio | - | - | 0.14 | 0.33 |
ZyVersa Therapeutics Quarterly Data | ||||||||||||
Dec20 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
PB Ratio | Get a 7-Day Free Trial | 0.14 | 0.18 | 0.29 | 0.29 | 0.33 |
For the Biotechnology subindustry, ZyVersa Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where ZyVersa Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ZyVersa Therapeutics's PB Ratio for today is calculated as follows:
PB Ratio | = | Share Price | / | Book Value per Share (Q: Dec. 2023) |
= | 4.4872 | / | 27.332 | |
= | 0.16 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
PB Ratio | = | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock) |
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
ZyVersa Therapeutics (NAS:ZVSA) PB Ratio Explanation
Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Thank you for viewing the detailed overview of ZyVersa Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Pablo A. Guzman | officer: Chief Medical Officer | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Gregory Gene Freitag | director | 13631 PROGRESS BLVD., ALACHUA FL 32615 |
Katrin Rupalla | director | 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
James Sapirstein | director | 1517 SAN JACINTO, HOUSTON TX 77002 |
Stephen C. Glover | director, officer: Chief Executive Officer | 108 DOCKSIDE CIRCLE, WESTON FL 33327 |
Labella Nicholas A. Jr. | officer: Chief Scientific Officer | C/O INSMED INCORPORATED, 8720 STONY POINT PKWY, SUITE 200, RICHMOND VA 23235 |
Peter Wolfe | officer: Chief Financial Officer | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Karen A. Cashmere | officer: Chief Commercial Officer | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Min-chul Park | director | C/O ZYVERSA THERAPEUTICS, INC., 2200 N. COMMERCE PARKWAY, WESTON FL 33326 |
Incon Co., Ltd. | 10 percent owner | 4/F 16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI M5 14042 |
Robert G Finizio | director | 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487 |
Raj Mehra | director | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
David S. Briones | director, officer: Chief Financial Officer | C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056 |
Daniel J. O'connor | director, officer: Chief Executive Officer | C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022 |
A.g.p. / Alliance Global Partners Corp. | 10 percent owner | 88 POST ROAD WEST, 2ND FLOOR, WESTPORT CT 06880 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 05-19-2023
By Marketwired • 10-18-2023
By sperokesalga sperokesalga • 04-27-2023
By Marketwired • 09-22-2023
By sperokesalga sperokesalga • 05-15-2023
By sperokesalga sperokesalga • 06-20-2023
By sperokesalga sperokesalga • 05-25-2023
By Marketwired • 09-27-2023
By sperokesalga sperokesalga • 05-09-2023
By sperokesalga sperokesalga • 05-01-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.